查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球急性集群性癫痫市场 - 全球产业分析、规模、份额、成长、趋势、区域展望、预测（2023-2030）
市场调查报告书
商品编码
1371541

全球急性集群性癫痫市场 - 全球产业分析、规模、份额、成长、趋势、区域展望、预测（2023-2030）

Acute Repetitive Seizures Market - Global Acute Repetitive Seizures Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 -
出版日期: | 出版商: Fairfield Market Research | 英文 240 Pages | 商品交期: 2-5个工作天内

价格
简介目录

到 2030 年，全球急性癫痫群聚市场规模预计将达到 135 亿美元，2023 年至 2030 年复合年增长率为 30%。

推动急性癫痫群发市场的主要趋势之一是充分控制癫痫发作的治疗差距。 目前许多患者无法获得有效的治疗，凸显了对创新治疗的需求，并促使製药公司投资研发 (R&D)。 这不仅改善了患者护理，也代表着巨大的市场机会。

全球医疗保健产业的快速扩张也是刺激急性丛集性癫痫市场的一大趋势。 随着医疗保健基础设施的发展，获得医疗服务的机会和有效癫痫管理的需求也在增加。 该市场有望受益于全球医疗保健产业的扩张。

由于已确定的功效、多样化的选择以及持续的研发努力，导致配方改进和副作用减少，抗癫痫药物 (AED) 在急性丛集性癫痫市场中经历了显着增长。 AED 已成为癫痫发作管理的可行选择。

由于口服 AED 形式的便利性、患者依从性和广泛可用性，口服给药在急性癫痫集簇市场中变得越来越重要。 这种非侵入性方法简化了长期癫痫管理并有助于市场成长。

医院已成为急性发作集群市场的主要分销管道，并已成为急性发作管理的主要中心。 同时，在以患者为中心的护理、行动医疗设备和远距医疗趋势的推动下，家庭护理正在发展成为一种高效、便捷的家庭护理形式。

本报告研究了全球急性癫痫集群市场，并提供了市场概述，以及按药物类型、给药途径、分销渠道、最终用途、区域和进入市场的竞争对手划分的趋势。我们提供趋势、 ETC 。

目录

第 1 章执行摘要

第二章市场概述

  • 市场定义与细分
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影响分析
  • 乌克兰和俄罗斯之间衝突的影响
  • 经济概况
  • 杵分析

第 3 章 2018-2030 年全球急性丛集性癫痫市场展望

  • 2018-2030 年全球急性丛集性癫痫市场展望（按药物类型、价值（十亿美元）划分）
  • 2018-2030 年全球急性癫痫群聚市场前景（按给药途径划分）、价值（十亿美元）
  • 2018-2030 年全球急性丛集性癫痫市场展望，按分销管道划分，价值（十亿美元）
  • 2018-2030 年全球急性丛集性癫痫市场展望（按最终用途划分）、价值（十亿美元）
  • 2018-2030 年全球急性丛集性缉获市场前景（按地区、价值（十亿美元））

第 4 章北美急性丛集性癫痫市场展望，2018-2030

第五章欧洲急性丛集性癫痫市场展望，2018-2030

第 6 章亚太地区急性丛集性癫痫市场展望，2018-2030 年

第 7 章拉丁美洲急性丛集性癫痫市场展望，2018-2030 年

第 8 章中东与非洲急性丛集性癫痫市场展望，2018-2030 年

第九章竞争态势

  • 分销通路和应用程式的热图
  • 製造商和应用程式的热图
  • 2022 年公司市占率分析
  • 竞争力仪表板
  • 公司简介
    • Pfizer
    • Novartis
    • GlaxoSmithKline
    • Eisai Co. Ltd.
    • UCB Pharmaceuticals
    • Lundbeck
    • UCB
    • Acquestive Therapeutics
    • Marinus Pharmaceuticals
    • Takeda Pharmaceuticals
    • SK Biopharmaceuticals
    • Supernus Pharmaceuticals
    • Neurelis Inc.
    • Sage Therapeutics
    • NeuroPace

第 10 章附录

  • 调查方法
  • 报告先决条件
  • 首字母缩写词和缩写词
简介目录

Global Acute Repetitive Seizures Market Projected to Reach $13.5 Billion by 2030: Rapid Growth and Key Trends Shape the Industry.

The global acute repetitive seizures market is on a trajectory of remarkable growth, with projections indicating a market size of $13.5 billion by the end of 2030, driven by a robust CAGR of 30% between 2023 and 2030. Fairfield Market Research's latest report provides a comprehensive overview of this burgeoning market, highlighting key trends, growth determinants, and the competitive landscape.

Key Trends Driving Growth in the Acute Repetitive Seizures Market

Presence of a Treatment Gap and R&D Initiatives: One of the primary trends propelling the acute repetitive seizures market is the presence of a treatment gap in achieving adequate seizure control. Many patients currently lack access to effective therapies, highlighting the demand for innovative treatments and prompting pharmaceutical companies to invest in research and development (R&D). This not only enhances patient care but also represents a significant market opportunity.

Rapidly Expanding Global Healthcare Industry: The global healthcare industry's rapid expansion is another major trend fueling the acute repetitive seizures market. As healthcare infrastructure grows, so does access to care and the demand for effective seizure management. The market is set to profit from the worldwide healthcare industry's expansion.

Dominance of Antiepileptic Drugs (AEDs): Antiepileptic drugs (AEDs) are experiencing significant growth in the acute repetitive seizures market due to their well-established efficacy, diverse options, and continuous R&D efforts leading to improved formulations and reduced side effects. AEDs have become the preferred choice for seizure management.

Growing Importance of the Oral Route: The oral route of administration is gaining prominence in the acute repetitive seizures market due to its convenience, patient compliance, and the wide availability of AEDs in oral forms. This non-invasive method simplifies long-term seizure management, contributing to its growth.

Hospitals and Home Care Settings: Hospitals are emerging as a key distribution channel in the acute repetitive seizures market, serving as primary centers for acute seizure management. In contrast, home care settings are growing due to the trend toward patient-centric care, portable medical devices, and telemedicine, making home care efficient and convenient.

Regional Insights

North America Leads the Way: North America has captured the largest market share in the acute repetitive seizures market. This dominance is attributed to its advanced healthcare infrastructure, high disease prevalence, strong R&D investments, favorable regulations, and a robust pharmaceutical industry. North America plays a dominant role in seizure management and treatment.

Asia Pacific Shows Exceptional Growth: The Asia Pacific region is poised to witness the highest CAGR in the acute repetitive seizures market. Factors such as a large patient population, increasing healthcare infrastructure, rising awareness, and expanding access to care are driving remarkable growth in this rapidly evolving market.

Competitive Landscape

The global acute repetitive seizures market is characterized by consolidation, with a select group of major players dominating the industry. These key players, including Pfizer, Novartis, GlaxoSmithKline, Eisai Co., Ltd, UCB Pharmaceuticals, Lundbeck, UCB, Aquestive Therapeutics, Marinus Pharmaceuticals, Takeda Pharmaceuticals, SK Biopharmaceuticals, Supernus Pharmaceuticals, Neurelis, Inc., Sage Therapeutics, NeuroPace, Inc and others, are actively introducing new products and expanding their distribution channels to bolster their international presence.

Table of Contents

1. Executive Summary

  • 1.1. Global Acute Repetitive Seizures Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2022
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. Covid-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Acute Repetitive Seizures Market Outlook, 2018 - 2030

  • 3.1. Global Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
    • 3.1.1. Key Highlights
      • 3.1.1.1. Antiepileptic Drugs (AEDs)
      • 3.1.1.2. Benzodiazepines
      • 3.1.1.3. Barbiturates
      • 3.1.1.4. Others
  • 3.2. Global Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 3.2.1. Key Highlights
      • 3.2.1.1. Oral
      • 3.2.1.2. Intravenous
      • 3.2.1.3. Intranasal
  • 3.3. Global Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 3.3.1. Key Highlights
      • 3.3.1.1. Hospitals
      • 3.3.1.2. Specialty Clinics
      • 3.3.1.3. Retail Pharmacies
      • 3.3.1.4. Online Pharmacies
  • 3.4. Global Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 3.4.1. Key Highlights Snacks
      • 3.4.1.1. Hospitals
      • 3.4.1.2. Clinics
      • 3.4.1.3. Home Care Settings
  • 3.5. Global Acute Repetitive Seizures Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Acute Repetitive Seizures Market Outlook, 2018 - 2030

  • 4.1. North America Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
    • 4.1.1. Key Highlights
      • 4.1.1.1. Antiepileptic Drugs (AEDs)
      • 4.1.1.2. Benzodiazepines
      • 4.1.1.3. Barbiturates
      • 4.1.1.4. Others
  • 4.2. North America Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 4.2.1. Key Highlights
      • 4.2.1.1. Oral
      • 4.2.1.2. Intravenous
      • 4.2.1.3. Intranasal
  • 4.3. North America Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 4.3.1. Key Highlights
      • 4.3.1.1. Hospitals
      • 4.3.1.2. Specialty Clinics
      • 4.3.1.3. Retail Pharmacies
      • 4.3.1.4. Online Pharmacies
  • 4.4. North America Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospitals
      • 4.4.1.2. Clinics
      • 4.4.1.3. Home Care Settings
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis
  • 4.5. North America Acute Repetitive Seizures Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 4.5.1.2. U.S. Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 4.5.1.3. U.S. Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 4.5.1.4. U.S. Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 4.5.1.5. Canada Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 4.5.1.6. Canada Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 4.5.1.7. Canada Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 4.5.1.8. Canada Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Acute Repetitive Seizures Market Outlook, 2018 - 2030

  • 5.1. Europe Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
    • 5.1.1. Key Highlights
      • 5.1.1.1. Antiepileptic Drugs (AEDs)
      • 5.1.1.2. Benzodiazepines
      • 5.1.1.3. Barbiturates
      • 5.1.1.4. Others
  • 5.2. Europe Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 5.2.1. Key Highlights
      • 5.2.1.1. Oral
      • 5.2.1.2. Intravenous
      • 5.2.1.3. Intranasal
  • 5.3. Europe Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospitals
      • 5.3.1.2. Specialty Clinics
      • 5.3.1.3. Retail Pharmacies
      • 5.3.1.4. Online Pharmacies
  • 5.4. Europe Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospitals
      • 5.4.1.2. Clinics
      • 5.4.1.3. Home Care Settings
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis
  • 5.5. Europe Acute Repetitive Seizures Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.2. Germany Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.5.1.3. Germany Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.5.1.4. Germany Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 5.5.1.5. U.K. Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.6. U.K. Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.5.1.7. U.K. Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.5.1.8. U.K. Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 5.5.1.9. France Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.10. France Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.5.1.11. France Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.5.1.12. France Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 5.5.1.13. Italy Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.14. Italy Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.5.1.15. Italy Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.5.1.16. Italy Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 5.5.1.17. Spain Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.18. Spain Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.5.1.19. Spain Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.5.1.20. Spain Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 5.5.1.21. Rest of Europe Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.22. Rest of Europe Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.5.1.23. Rest of Europe Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.5.1.24. Rest of Europe Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Acute Repetitive Seizures Market Outlook, 2018 - 2030

  • 6.1. Asia Pacific Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
    • 6.1.1. Key Highlights
      • 6.1.1.1. Antiepileptic Drugs (AEDs)
      • 6.1.1.2. Benzodiazepines
      • 6.1.1.3. Barbiturates
      • 6.1.1.4. Others
  • 6.2. Asia Pacific Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 6.2.1. Key Highlights
      • 6.2.1.1. Oral
      • 6.2.1.2. Intravenous
      • 6.2.1.3. Intranasal
  • 6.3. Asia Pacific Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospitals
      • 6.3.1.2. Specialty Clinics
      • 6.3.1.3. Retail Pharmacies
      • 6.3.1.4. Online Pharmacies
  • 6.4. Asia Pacific Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospitals
      • 6.4.1.2. Clinics
      • 6.4.1.3. Home Care Settings
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis
  • 6.5. Asia Pacific Acute Repetitive Seizures Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 6.5.1.2. China Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 6.5.1.3. China Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.5.1.4. China Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 6.5.1.5. Japan Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 6.5.1.6. Japan Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 6.5.1.7. Japan Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.5.1.8. Japan Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 6.5.1.9. India Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 6.5.1.10. India Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 6.5.1.11. India Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.5.1.12. India Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 6.5.1.13. Southeast Asia Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 6.5.1.14. Southeast Asia Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 6.5.1.15. Southeast Asia Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.5.1.16. Southeast Asia Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 6.5.1.17. Rest of Asia Pacific Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 6.5.1.18. Rest of Asia Pacific Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 6.5.1.19. Rest of Asia Pacific Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.5.1.20. Rest of Asia Pacific Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Acute Repetitive Seizures Market Outlook, 2018 - 2030

  • 7.1. Latin America Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
    • 7.1.1. Key Highlights
      • 7.1.1.1. Antiepileptic Drugs (AEDs)
      • 7.1.1.2. Benzodiazepines
      • 7.1.1.3. Barbiturates
      • 7.1.1.4. Others
  • 7.2. Latin America Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 7.2.1. Key Highlights
      • 7.2.1.1. Oral
      • 7.2.1.2. Intravenous
      • 7.2.1.3. Intranasal
  • 7.3. Latin America Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospitals
      • 7.3.1.2. Specialty Clinics
      • 7.3.1.3. Retail Pharmacies
      • 7.3.1.4. Online Pharmacies
  • 7.4. Latin America Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospitals
      • 7.4.1.2. Clinics
      • 7.4.1.3. Home Care Settings
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis
  • 7.5. Latin America Acute Repetitive Seizures Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 7.5.1.2. Brazil Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 7.5.1.3. Brazil Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 7.5.1.4. Brazil Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 7.5.1.5. Mexico Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 7.5.1.6. Mexico Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 7.5.1.7. Mexico Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 7.5.1.8. Mexico Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 7.5.1.9. Rest of Latin America Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 7.5.1.10. Rest of Latin America Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 7.5.1.11. Rest of Latin America Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 7.5.1.12. Rest of Latin America Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Acute Repetitive Seizures Market Outlook, 2018 - 2030

  • 8.1. Middle East & Africa Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
    • 8.1.1. Key Highlights
      • 8.1.1.1. Antiepileptic Drugs (AEDs)
      • 8.1.1.2. Benzodiazepines
      • 8.1.1.3. Barbiturates
      • 8.1.1.4. Others
  • 8.2. Middle East & Africa Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 8.2.1. Key Highlights
      • 8.2.1.1. Oral
      • 8.2.1.2. Intravenous
      • 8.2.1.3. Intranasal
  • 8.3. Middle East & Africa Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospitals
      • 8.3.1.2. Specialty Clinics
      • 8.3.1.3. Retail Pharmacies
      • 8.3.1.4. Online Pharmacies
  • 8.4. Middle East & Africa Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospitals
      • 8.4.1.2. Clinics
      • 8.4.1.3. Home Care Settings
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis
  • 8.5. Middle East & Africa Acute Repetitive Seizures Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 8.5.1.2. GCC Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 8.5.1.3. GCC Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 8.5.1.4. GCC Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 8.5.1.5. South Africa Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 8.5.1.6. South Africa Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 8.5.1.7. South Africa Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 8.5.1.8. South Africa Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 8.5.1.9. Rest of Middle East & Africa Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 8.5.1.10. Rest of Middle East & Africa Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 8.5.1.11. Rest of Middle East & Africa Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 8.5.1.12. Rest of Middle East & Africa Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Distribution Channel vs Application Heatmap
  • 9.2. Manufacturer vs Application Heatmap
  • 9.3. Company Market Share Analysis, 2022
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Pfizer
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Novartis
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. GlaxoSmithKline
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Eisai Co. Ltd.
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. UCB Pharmaceuticals
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Lundbeck
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. UCB
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Acquestive Therapeutics
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Business Strategies and Development
    • 9.5.9. Marinus Pharmaceuticals
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Takeda Pharmaceuticals
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development
    • 9.5.11. SK Biopharmaceuticals
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Product Portfolio
      • 9.5.11.3. Financial Overview
      • 9.5.11.4. Business Strategies and Development
    • 9.5.12. Supernus Pharmaceuticals
      • 9.5.12.1. Company Overview
      • 9.5.12.2. Product Portfolio
      • 9.5.12.3. Financial Overview
      • 9.5.12.4. Business Strategies and Development
    • 9.5.13. Neurelis Inc.
      • 9.5.13.1. Company Overview
      • 9.5.13.2. Product Portfolio
      • 9.5.13.3. Financial Overview
      • 9.5.13.4. Business Strategies and Development
    • 9.5.14. Sage Therapeutics
      • 9.5.14.1. Company Overview
      • 9.5.14.2. Product Portfolio
      • 9.5.14.3. Financial Overview
      • 9.5.14.4. Business Strategies and Development
    • 9.5.15. NeuroPace
      • 9.5.15.1. Company Overview
      • 9.5.15.2. Product Portfolio
      • 9.5.15.3. Financial Overview
      • 9.5.15.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations